Erwin G. Van Meir
- Molecular Biology top 0.5%
- Cancer Research top 0.1%
- Oncology top 0.5%
- Genetics top 0.1%
- Immunology top 0.5%
- Co-authors
- Daniel J. BratNicolas de TriboletBalveen KaurAnita C. BellailJeffrey J. OlsonCostas G. HadjipanayisDawn E. PostAnnie‐Claire Diserens
- Topics
- Glioma Diagnosis and Treatment (40 papers)Cancer, Hypoxia, and Metabolism (39 papers)Cancer-related Molecular Pathways (26 papers)
- Partner nations
- United StatesSwitzerlandJapan
In The Last Decade
Erwin G. Van Meir
170 papers receiving 15.9k citations
Hit Papers
Peers
Comparison fields: 5 of 156
- Molecular Biology 9.2k
- Cancer Research 4.7k
- Oncology 3.9k
- Genetics 3.5k
- Immunology 2.9k
Countries citing papers authored by Erwin G. Van Meir
This map shows the geographic impact of Erwin G. Van Meir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erwin G. Van Meir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erwin G. Van Meir more than expected).
Fields of papers citing papers by Erwin G. Van Meir
This network shows the impact of papers produced by Erwin G. Van Meir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erwin G. Van Meir. The network helps show where Erwin G. Van Meir may publish in the future.
Co-authorship network of co-authors of Erwin G. Van Meir
This figure shows the co-authorship network connecting the top 25 collaborators of Erwin G. Van Meir. A scholar is included among the top collaborators of Erwin G. Van Meir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erwin G. Van Meir. Erwin G. Van Meir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 3 | |
| 3 | 63 | |
| 4 | 8 | |
| 5 | 37 | |
| 6 | 52 | |
| 7 | 52 | |
| 8 | Efficacy of A Novel Anti-tumor Agent KCN1 in the Control of Ocular Melanoma In vitro and In vivo | 1 |
| 9 | 71 | |
| 10 | 52 | |
| 11 | 62 | |
| 12 | 73 | |
| 13 | 418 | |
| 14 | 114 | |
| 15 | 98 | |
| 16 | 99 | |
| 17 | 90 | |
| 18 | 31 | |
| 19 | 152 | |
| 20 | 9 |
About Erwin G. Van Meir
Erwin G. Van Meir is a scholar working on Cancer Research, Genetics and Immunology and Allergy, having authored 171 papers that have together received 16.2k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (40 papers), Cancer, Hypoxia, and Metabolism (39 papers) and Cancer-related Molecular Pathways (26 papers). The work is most often cited by research in Genetics (3.5k citations), Cancer Research (4.7k citations) and Immunology and Allergy (881 citations). Erwin G. Van Meir has collaborated with scholars based in United States, Switzerland and Japan. Frequent co-authors include Daniel J. Brat, Nicolas de Tribolet, Balveen Kaur, Anita C. Bellail, Jeffrey J. Olson, Costas G. Hadjipanayis, Dawn E. Post, Annie‐Claire Diserens, Satoru Osuka and Marie‐France Hamou. Their work appears in journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.